Impact Factor 5.085 | CiteScore 5.4
More on impact ›

Correction ARTICLE

Front. Immunol., 18 November 2020 | https://doi.org/10.3389/fimmu.2020.615755

Corrigendum: Effective Anti-tumor Response by TIGIT Blockade Associated With FcγR Engagement and Myeloid Cell Activation

Jin-Hwan Han, Mingmei Cai, Jeffery Grein, Samanthi Perera, Hongmei Wang, Mike Bigler, Roenna Ueda, Thomas W. Rosahl, Elaine Pinheiro, Drake LaFace, Wolfgang Seghezzi and Sybil M. Genther Williams*
  • Merck & Co. Inc., Kenilworth, NJ, United States

A Corrigendum on
Effective Anti-tumor Response by TIGIT Blockade Associated With FcγR Engagement and Myeloid Cell Activation

By Han J-H, Cai M, Grein J, Perera S, Wang H, Bigler M, Ueda R, Rosahl TW, Pinheiro E, LaFace D, Seghezzi W and Williams SMG. Front. Immunol. (2020) 11:573405. doi: 10.3389/fimmu.2020.573405

In the original article, there was a mistake in Figure 6 as published. While upgrading the figure with a high resolution for publication, the “on-figure” legend describing each experimental group was depicted inconsistently from the rest of the article. The corrected Figure 6 appears below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

FIGURE 6
www.frontiersin.org

Figure 6 Enhanced immune activation in tumors by anti-PD-1 can be achieved only when anti-TIGIT antibody has a functional Fc. (A–I) In order to gain molecular insights of anti-PD-1 and anti-TIGIT combination for anti-tumor responses, anti-PD-1 in the presence or absence of anti-TIGIT with mIgG1* or mIgG2a isotype were therapeutically treated in CT26 tumor-bearing mice. Four days after the second dose of each group (n = 10 per group), all the tumors were isolated and processed for real-time PCR. Relative gene expression profile of (A) CD45, (B) CD3+, (C) CD11b, (D) CD3+/CD11b ratio, (E) CD8b, (F) Foxp3, (G) IFN-g, (H) Perforin, and (I) Granzyme B. (J, K) In an independent experiment, indicated antibody regimen were injected to CT26 tumor-bearing mice every 4 days. The whole tumors were harvested untreated (day 0), 2 days after first injection (day 2), 4 days after first injection (day 4), 2 days after second injection (day 6), and 4 days after second injection (day 8). Each symbol represents average and standard error of 10 tumors from each group at each time point for the analysis of (J) Perforin and (K) Granzyme B. Orange arrow heads indicate the time points of antibody treatments. ns, not significant; *p < 0.05; **p < 0.01; ***p < 0.005; ****p < 0.001.

Keywords: TIGIT, FcγR, myeloid cells, combination cancer immunotherapy, costimulatory molecules, immune checkpoint blockade

Citation: Han J-H, Cai M, Grein J, Perera S, Wang H, Bigler M, Ueda R, Rosahl TW, Pinheiro E, LaFace D, Seghezzi W and Williams SMG (2020) Corrigendum: Effective Anti-tumor Response by TIGIT Blockade Associated With FcγR Engagement and Myeloid Cell Activation. Front. Immunol. 11:615755. doi: 10.3389/fimmu.2020.615755

Received: 09 October 2020; Accepted: 20 October 2020;
Published: 18 November 2020.

Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2020 Han, Cai, Grein, Perera, Wang, Bigler, Ueda, Rosahl, Pinheiro, LaFace, Seghezzi and Williams. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Sybil M. Genther Williams, sybil_williams@merck.com